公开(公告)号：US11648264B2

公开(公告)日：2023-05-16

申请号：US16723840

申请日：2019-12-20

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Samuel Strober ,  Robert Lowsky

IPC分类号： A61K35/12 ,  A61K35/28 ,  A61K35/22 ,  A61K35/14 ,  A61K38/19 ,  A61K41/00 ,  A61K45/06 ,  A61K31/365 ,  A61K31/436 ,  A61K31/573 ,  A61K38/13 ,  A61K39/00 ,  A61K39/395 ,  A61N5/10 ,  A61K35/17

CPC分类号： A61K35/12 ,  A61K31/365 ,  A61K31/436 ,  A61K31/573 ,  A61K35/14 ,  A61K35/17 ,  A61K35/22 ,  A61K35/28 ,  A61K38/13 ,  A61K38/193 ,  A61K39/001 ,  A61K39/39541 ,  A61K41/00 ,  A61K45/06 ,  A61N5/10 ,  A61K39/395 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/515 ,  A61K2039/54 ,  A61K2039/57 ,  A61K35/14 ,  A61K2300/00 ,  A61K35/22 ,  A61K2300/00 ,  A61K35/28 ,  A61K2300/00 ,  A61K38/193 ,  A61K2300/00

摘要： Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

公开(公告)号：US20190240351A1

公开(公告)日：2019-08-08

申请号：US15789138

申请日：2017-10-20

申请人： ModernaTX, Inc.

发明人： Stephane BANCEL ,  Tirtha CHAKRABORTY ,  Antonin DE FOUGEROLLES ,  Sayda M. ELBASHIR ,  Jeff Lynn ELLSWORTH ,  Kenechi EJEBE ,  Justin GUILD ,  Matthias JOHN ,  Paul HATALA ,  Atanu ROY ,  Jason P. SCHRUM ,  Susan WHORISKEY ,  Kristy M. WOOD

IPC分类号： A61K48/00 ,  C07K14/535 ,  C07K14/47 ,  C07K14/515 ,  A61K9/127 ,  C12N9/64 ,  A61K31/7115 ,  A61K47/54 ,  A61K9/51 ,  A61K9/14 ,  C12N15/87 ,  C12N15/85 ,  C12N9/00 ,  C07K14/705 ,  C07K14/62 ,  C07K14/505 ,  C07K14/485 ,  C07K14/435 ,  A61K38/45 ,  A61K38/17 ,  A61K38/48 ,  C07K14/525 ,  C07K14/56 ,  C07K16/00 ,  C12P21/00 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  C12P13/04 ,  C12N15/52 ,  C12N15/11 ,  C12N9/88 ,  C12N9/42 ,  C12N9/24 ,  C12N9/16 ,  C12N9/10 ,  C07K14/005

CPC分类号： A61K48/0066 ,  A61K9/1271 ,  A61K9/145 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/45 ,  A61K38/4846 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/43595 ,  C07K14/47 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/4723 ,  C07K14/4746 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/5418 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/40 ,  C12N9/0069 ,  C12N9/0091 ,  C12N9/1051 ,  C12N9/1241 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/6435 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/6443 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y113/12007 ,  C12Y116/03001 ,  C12Y207/07012 ,  C12Y304/21007 ,  C12Y304/21022 ,  C12Y304/21027 ,  C12Y403/02001 ,  C12Y603/02019 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/423 ,  Y02A50/463 ,  Y02A50/491

摘要： The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20190240267A1

公开(公告)日：2019-08-08

申请号：US16116223

申请日：2018-08-29

申请人： Evelo Biosciences, Inc.

发明人： Brian Goodman ,  Peter Sandy ,  Jacqueline Papkoff ,  Humphrey Gardner ,  Holly Ponichtera

IPC分类号： A61K35/742 ,  A61P35/00 ,  C12R1/01 ,  A61K45/06

CPC分类号： A61K35/742 ,  A61K35/74 ,  A61K38/19 ,  A61K38/193 ,  A61K38/217 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C12N1/20 ,  C12R1/01

摘要： Provided herein are methods and compositions related to Blautia Strain A useful as therapeutic agents.

公开(公告)号：US20190216897A1

公开(公告)日：2019-07-18

申请号：US16308002

申请日：2017-06-07

申请人： Eynav Klechevsky

发明人： Eynav Klechevsky

IPC分类号： A61K38/20 ,  G01N33/569 ,  A61K39/395 ,  A61K38/19 ,  A61K45/06 ,  A61P17/06 ,  C12N5/0784 ,  A61K35/15 ,  A61P35/00

CPC分类号： A61K38/2026 ,  A61K35/15 ,  A61K38/19 ,  A61K38/191 ,  A61K38/193 ,  A61K38/20 ,  A61K38/212 ,  A61K38/217 ,  A61K39/3955 ,  A61K45/06 ,  A61P17/06 ,  A61P35/00 ,  A61P37/02 ,  C12N5/0639 ,  C12N2506/11 ,  G01N33/50 ,  G01N33/56977 ,  A61K2300/00

摘要： The present disclosure provides for methods and compositions for the modulation of CD5 in a subject. Also provided are methods of detecting and monitoring diseases, such as inflammatory and autoimmune diseases.

公开(公告)号：US20190216773A1

公开(公告)日：2019-07-18

申请号：US16107761

申请日：2018-08-21

申请人： Genzyme Corporation

发明人： Gary J. BRIDGER ,  Michael J. ABRAMS ,  Geoffrey W. HENSON ,  Ronald Trevor MACFARLAND ,  Gary B. CALANDRA ,  Hal E. BROXMEYER ,  David C. DALE

IPC分类号： A61K31/395 ,  A61K31/555 ,  C12N5/0789 ,  A61K35/28 ,  A61K38/19 ,  A61K31/33 ,  A61K31/551 ,  A61K31/55 ,  A61K31/496 ,  A61K31/4427

CPC分类号： A61K31/395 ,  A61K31/33 ,  A61K31/4427 ,  A61K31/496 ,  A61K31/55 ,  A61K31/551 ,  A61K31/555 ,  A61K35/28 ,  A61K38/193 ,  A61K38/195 ,  A61K2035/124 ,  C12N5/0647 ,  A61K2300/00

摘要： Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z′  (1) or pharmaceutically acceptable salt thereof wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system; or Z is of the formula wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1-20 atoms, Z′ may be embodied in a form as defined by Z above, or alternatively may be of the formula —N(R)—(CR2)n—X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.

公开(公告)号：US20190209512A1

公开(公告)日：2019-07-11

申请号：US16357013

申请日：2019-03-18

申请人： CHS Pharma, Inc.

发明人： Jang-Yen Wu ,  Howard Malcolm Prentice

IPC分类号： A61K31/27 ,  A61K31/192 ,  A61K38/19

CPC分类号： A61K31/27 ,  A61K31/192 ,  A61K38/193 ,  A61K2300/00

摘要： Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.

公开(公告)号：US20190201392A1

公开(公告)日：2019-07-04

申请号：US16224129

申请日：2018-12-18

申请人： IRR, INC.

发明人： Bruce Chandler May

IPC分类号： A61K31/495 ,  A61K31/573 ,  A61K31/519 ,  A61K31/47 ,  A61K31/454 ,  A61K38/19 ,  A61K31/496 ,  A61K31/135 ,  A61K31/4985 ,  A61K31/136

CPC分类号： A61K31/495 ,  A61K31/135 ,  A61K31/136 ,  A61K31/454 ,  A61K31/47 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/573 ,  A61K38/193 ,  A61K2300/00

摘要： The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

公开(公告)号：US20180273601A1

公开(公告)日：2018-09-27

申请号：US15757276

申请日：2016-09-02

申请人： Memorial Sloan Kettering Cancer Center

发明人： Prasad S. Adusumilli ,  Michel Sadelain

IPC分类号： C07K14/725 ,  A61K35/17 ,  A61K38/20 ,  C07K16/30 ,  C07K14/705 ,  A61K39/395 ,  A61K38/17 ,  C12N9/64 ,  A61K38/48 ,  A61P35/00

CPC分类号： C07K14/7051 ,  A61K35/17 ,  A61K35/28 ,  A61K38/00 ,  A61K38/177 ,  A61K38/1774 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/4873 ,  A61K39/0011 ,  A61K39/39558 ,  A61P35/00 ,  C07K14/70503 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6472 ,  C12N2510/00 ,  C12Y304/22062 ,  A61K2300/00

摘要： Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.

公开(公告)号：US20180256751A1

公开(公告)日：2018-09-13

申请号：US15892265

申请日：2018-02-08

申请人： SILLAJEN BIOTHERAPEUTICS, INC.

发明人： David KIRN

IPC分类号： A61K48/00 ,  A61K45/06 ,  A61K35/768 ,  A61K38/19 ,  A61N5/10 ,  A61K9/00 ,  A61K38/20

CPC分类号： A61K48/0066 ,  A61K9/0019 ,  A61K35/768 ,  A61K38/191 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/208 ,  A61K45/06 ,  A61K48/00 ,  A61K48/0075 ,  A61N5/10 ,  C12N2710/24132 ,  A61K2300/00

摘要： Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.

公开(公告)号：US20180222951A1

公开(公告)日：2018-08-09

申请号：US15749214

申请日：2016-08-03

申请人： The United States of America,as represented by the Secretary, Department of Health and human Service

发明人： Jeffrey Schlom ,  Claudia M. Palena

IPC分类号： C07K14/47 ,  A61K38/17 ,  A61K45/06 ,  A61K38/19 ,  A61K9/127 ,  A61P35/00 ,  C12N15/86 ,  A61K39/00

CPC分类号： C07K14/4702 ,  A61K9/127 ,  A61K38/1709 ,  A61K38/193 ,  A61K39/0011 ,  A61K39/001152 ,  A61K39/00117 ,  A61K39/001182 ,  A61K45/06 ,  A61K2039/5256 ,  A61K2039/70 ,  A61P35/00 ,  C12N15/86 ,  C12N2710/10043 ,  Y02A50/466

摘要： The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.